Latest stories on SLBT
SL Science Holding Limited Non-GAAP EPS of $0.00, revenue of $1.38B
Seeking Alpha48 · neutralearnings
SL Science Holding Limited Reports First Half 2026 Financial Results
GlobeNewswire63 · neutralearnings
SL Science Holding Limited Reports First Half 2026 Financial Results
Business Insider63 · neutralearnings
SL Science: A $1.15 Billion Valuation Built On Preclinical Promises
Seeking Alpha28 · bearishgeneral
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
GlobeNewswire67 · bullishgeneral
SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
Business Insider67 · bullishgeneral
SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
Business Insider63 · neutralproduct/pr
SLBT Stock Price, News, Quote & History
Quartz50 · neutralgeneral
SL Science Seeks FDA Orphan Drug Status for Gamma Delta T Cell Therapy in Glioblastoma
TipRanks63 · neutralproduct/pr
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
Business Insider56 · neutralproduct/pr
SL Science Highlights Strategic Shift and Major Pipeline Progress Amid Wider Losses in FY 2025
MarketChameleon52 · neutralgeneral
SL Science Holding Limited Reports Full Year 2025 Financial Results | SLBT Stock News
StockTitan28 · bearishearnings
SL Science (SLBT) Lands Nasdaq Debut With $5.57 Billion Valuation and Ambitious Cell Therapy Platform
MarketChameleon73 · bullishgeneral
Why Is SL Science Stock (SLBT) Up Today?
TipRanks58 · neutralgeneral